How are the sub-unit pertussis vaccines to be evaluated?
- 19 October 1987
- journal article
- research article
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 99 (2) , 477-484
- https://doi.org/10.1017/s0950268800067984
Abstract
SUMMARY: Although an effective whooping cough vaccine has been available in the UK since the 1950s, its current association with neurotoxicity has resulted in poor uptake: as a consequence major epidemics (with significant morbidity and mortality) arc still being experienced.Component (sub-unit) vaccines, which incorporate those antigens thought to be concerned with generating a protective effect, have been developed and are now available for field testing. This paper addresses how such a vaccine might be evaluated, the organization of a trial and the difficulties to be expected.This publication has 14 references indexed in Scilit:
- Progress towards a new pertussis vaccine.BMJ, 1986
- Recognising whooping cough.BMJ, 1986
- SYMPTOMS AFTER PRIMARY IMMUNISATION WITH DTP AND WITH DT VACCINEThe Lancet, 1984
- Pyrexia after diphtheria/tetanus/pertussis and diphtheria/tetanus vaccines.Archives of Disease in Childhood, 1983
- Efficacy of pertussis vaccination in England. Report from the PHLS Epidemiological Research Laboratory and 21 area health authorities.BMJ, 1982
- An Evaluation of Pertussis VaccineClinical Infectious Diseases, 1979
- WHOOPING-COUGH IN HERTFORDSHIREThe Lancet, 1979
- VACCINATION AGAINST WHOOPING-COUGHThe Lancet, 1977
- Further experience of reactions, especially of a cerebral nature, in conjunction with triple vaccination: a study based on vaccinations in Sweden 1959-65.BMJ, 1967
- Neurological Complications of Pertussis ImmunizationBMJ, 1958